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BACKGROUND & AIMS: Tumor cells circulate in low numbers in
peripheral blood; their detection is used predominantly in meta-
static disease. We evaluated the feasibility and safety of sampling
portal venous blood via endoscopic ultrasound (EUS) to count
portal venous circulating tumor cells (CTCs), compared with
paired peripheral CTCs, in patients with pancreaticobiliary cancers
(PBCs). METHODS: In a single-center cohort study, we evaluated
18 patients with suspected PBCs. Under EUS guidance, a 19-gauge
EUS ﬁne needle was advanced transhepatically into the portal
vein and as many as four 7.5-mL aliquots of blood were aspirated.
Paired peripheral blood samples were obtained. Epithelial-derived
CTCs were sorted magnetically based on expression of epithelial
cell adhesion molecules; only those with a proper morphology and
found to be CD45 negative and positive for cytokeratins 8, 18, and/
or 19 and 40,6-diamidino-2-phenylindole were considered to be
CTCs. For 5 samples, CTCs alsowere isolated byﬂow cytometry and
based on CD45 depletion. ImageStream was used to determine the
relative protein levels of P16, SMAD4, and P53. DNA was extracted
from CTCs for sequencing of select KRAS codons. RESULTS: There
were no complications from portal vein blood acquisition. We
detectedCTCs inportal vein samples fromall 18patients (100%)vs
peripheral blood samples from only 4 patients (22.2%). Patients
with conﬁrmed PBCs had a mean of 118.4 ± 36.8 CTCs/7.5 mL
portal vein blood, compared with a mean of 0.8 ± 0.4 CTCs/7.5 mL
peripheral blood (P < .01). The 9 patients with nonmetastatic,
resectable, or borderline-resectable PBCs had amean of 83.2 CTCs/
7.5 mL portal vein blood (median, 62.0 CTCs/7.5 mL portal vein
blood). In a selected patient, portal vein CTCs were found to carry
the same mutations as those detected in a metastatic lymph node
and expressed similar levels of P16, SMAD4, and P53 proteins.
CONCLUSIONS: It is feasible and safe to collect portal venousblood
frompatients undergoing EUS.We identiﬁed CTCs in all portal vein
blood samples from patients with PBCs, but less than 25% of pe-
ripheral blood samples. Portal vein CTCs can be used formolecular
characterization of PBCs and share features of metastatic tissue.
This technique might be used to study the pathogenesis and pro-
gression of PBCs, as well as a diagnostic or prognostic tool to
stratify risk of cancer recurrence or developing metastases.rate; IHC, immunohistochemistry; PBC, pancreaticobiliary cancer; PC,
pancreatic cancer; PDAC, pancreatic ductal adenocarcinoma.
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your mobile device’s app store.ancreaticobiliary cancers (PBCs), encompassing pri-Pmary pancreatic and biliary tract cancers, frequently
progress silently until primary tumor growth or secondary
metastatic dissemination to distant organs becomes sufﬁcient
for the development of clinical symptoms. The presence of
local advancement or distant metastases often precludes
curative treatment and, as a result, the 5-year overall survival
rate in pancreatic cancer (PC) is 7%,with biliary tract cancers
onlymarginally better at 16%and 18%.1 Even in theminority
subset of PBC patients amenable to curative-intent resection
and adjuvant chemotherapy, the 5-year overall survival
prognoses remain unsatisfactory at approximately 20% to
30%2,3 because of the development of local recurrence or
distant metastases, the majority of which occur within only
2 years of resection.4,5
Because of the meager survival outcomes combined with a
current inability to assess tumor molecular heterogeneity or
perioperative risk of recurrence adequately, the clinical man-
agement of PBCs remains controversial. A prototypical
example is the subset of patients categorized as having
borderline resectable PC endorsed by multiple profes-
sional societies to include nonmetastatic disease with limited
vascular involvement.6 Traditionally, patients with non-
metastatic PC, including borderline resectable patients,
are assessed for surgical candidacy with preoperative
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sound (EUS). Consensus standard treatment has evolved into
surgical resection with adjuvant chemotherapy; however,
given the decreased likelihood of complete (R0), margin-
negative resection and poor outcomes, there has been
increased consideration for neo-adjuvant therapy. Neo-
adjuvant therapy theoretically may increase the ability to
achieve R0 resection, however, not only is there a lack of evi-
dence from prospective or randomized trials showing beneﬁts,
but also no clear method for deﬁning a successful response to
neo-adjuvant therapy because several reports have indicated
that standard cross-sectional radiologic imaging remains
insufﬁcient.7–9
In PBCs, there is still a signiﬁcant clinical need to deter-
mine individualized tumor molecular proﬁles and personal-
ized risk for recurrence, which may allow the following:
(1) better risk stratiﬁcation for postoperative recurrence,
(2) identiﬁcation of patients beneﬁting from aggressive neo-
adjuvant therapy, (3) sparing low-risk patients from poten-
tially unnecessary adjuvant therapy, and/or (4) sparing
high-risk patients from undergoing invasive surgery and the
associatedmorbidity andmortality risk that ultimatelywould
not improve survival.
Circulating tumor cells (CTCs) shed into the blood from
primary tumors hold promise in serving as an informative
biomarker to address this clinical need. CTCs have been
explored as aminimally invasive tool for assessing solid-tumor
burden, with subsequent analyses validating CTC enumera-
tion as a predictive and prognostic indicator of disease-free
progression and overall survival.10 However, peripheral
CTCs are extremely rare with estimates of 1 tumor cell per 1
billion circulating blood cells.11 This low value has been
attributed in part to CTC biophysical factors, including platelet
adhesion and circulating in clusters, irregular shapes, and at
sizes larger than capillaries, which in certain malignancies can
result in hepatic ﬁltration during portal circulation transit.12,13
The concerns of hepatic ﬁltration, further supported by loca-
tion patterns of PC tumor metastases, support the consider-
ation of a differential CTC yield by blood collection site.
This study evaluated the feasibility and safety of sampling
portal venous blood via EUS to enumerate epithelial cell
adhesion molecule (EpCAM)-positive (þ) portal venous
CTCs.14 We compared the number of CTCs obtained from theFigure 1. EUS-guided ac-
cess of the portal vein. (A)
The portal vein is identiﬁed
under EUS guidance with
Doppler wave veriﬁcation.
(B) EUS-guided, trans-
hepatic, FNA puncture of
the portal vein with a 19G
EUS FNA needle for portal
venous blood acquisition.
PV, portal vein.portal vein with peripheral blood in patients with non-
metastatic and metastatic PBCs and assessed the capability of
completing genomic and proteomic proﬁling of ﬂow-sorted,
isolated CTC fractions from EUS-obtained portal venous blood.Materials and Methods
Patient Selection
Eighteen patients referred for EUS with cross-sectional im-
aging and clinical symptoms consistent with PBCs were enrolled
prospectively with written consent in an Institutional Review
Board–approved study at the University of Chicago Medicine.
Portal Vein Sampling
EUS for PBC staging and/or diagnosis conﬁrmation with on-
site cytopathologic analysis of ﬁne-needle aspirates (FNA) was
performed in standard fashion. Under EUS guidance, the left
and right portal veins were identiﬁed. After verifying ﬂow
signal by Doppler, a 19-gauge EUS-FNA needle was advanced
transhepatically into the portal vein and 2–4 aliquots of 8.5 mL
blood were aspirated (Figure 1) and placed in CPT tubes
(catalog number: 02-685-125, Vacutainer Glass Mononuclear
Cell Preparation Tubes; BD, Franklin Lakes, NJ) and CellSave
Preservative Tubes (cat: 7900005; Janssen Diagnostics, LLC,
Raritan, NJ). The puncture site was monitored under EUS for
complications. Routine peripheral blood samples were obtained
before EUS in parallel and processed identically.
CTC Enumeration
For all patients (N ¼ 18), portal venous blood and periph-
eral blood samples were analyzed using the CellSearch Kit (cat:
7900001; Janssen Diagnostics, LLC) as previously described.15
In brief, 7.5 mL of whole peripheral blood and portal vein
blood were collected in CellSave Preservative Tubes containing
Na2–EDTA and cell preservative for the epithelial cells. The
buffy coat was isolated and epithelial-derived CTCs were sorted
magnetically by ferromagnetic labeling with surface anti-
EpCAM antibody. Isolated cells subsequently were stained for
intracellular anticytokeratins 8, 18, and/or 19 phycoerythrin
(PE) antibody, 40,6-diamidino-2-phenylindole (DAPI), and anti-
CD45 allophycocyanin (APC) antibody for leukocyte depletion.
Only epithelial cells with consistent, cell-like morphology that
were also cytokeratin 8, 18, and/or 19 þ, DAPIþ, and CD45-
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protocol, clusters identiﬁed by review were considered to be a
single event for enumeration purposes if fewer than 5 cells
were present.
Cell Sorting
In a subset of patients (n ¼ 5), whole peripheral and portal
venous blood samples were collected into CPT tubes and
centrifuged for 30 minutes at 1500g at room temperature as
previously described.16 Brieﬂy, the mononuclear layer cells
were isolated according to the manufacturer’s instructions and
washed twice with phosphate-buffered saline. Cells then were
stained with Alexa Fluor 488 EpCAM at 5 uL per million cells
(cat: 324210; Biolegend) and CD45 antibody at 1 uL per million
cells (cat: Q10156, QDot 800 CD45; Invitrogen) for 30 minutes
on ice. AGS cells (human gastric cancer cell line obtained from
ATCC, Manassas, VA) were prepared as an EpCAMþ control,
and unstained AGS cells served as negative controls. Cell sort-
ing was performed using standard procedure either by BD
FACSARIA III or a Bio-Rad S3 cell sorter. With ﬂow cytometry
CTC isolation, CD45-, EpCAMþ, and DAPIþ cells were collected
as CTC cells for further genomic and proteomic analyses.
Cell Live-Imaging
In a subset of patients (n¼ 5), mononuclear layer cells were
isolated as described earlier, washed, and depleted for
CD45- cells by anAutoMACSmachine (Miltenyi Biotec, SanDiego,
CA) after incubation with biotin anti-human CD45 (cat: 304004;
Biolegend, San Diego, CA) and antibiotin microbeads (cat: 120-
000-900; Miltenyi Biotec). CD45- cells were collected and ﬁxed
with 4% formaldehyde. The following day, the cells were stained
with EpCAM (5 uL per million cells) and CD45 (1 uL per million
cells) antibodies covered from light on ice for 30 minutes, and
then washed with phosphate-buffered saline. This was followed
by a cell membrane permeation step (Foxp3/Transcription
Factor Staining buffer kit, cat: 00-5523-00; eBioscience, San
Diego, CA), and cells were stained intracellularly for 1 hour
covered from light at room temperature for p53 (4 uL permillion
cells, PE anti-p53, cat: 645806; Biolegend), p16 (5 uL per million
cells, anti-CDKN2A/p16, Alexa Fluor 647, cat: bs-0740R-A647;
Bioss, Woburn, MA), smad4 (5 uL per million cells, anti-smad4,
PE Cy 5.5, cat: bs-0585R-PE-Cy5.5; Bioss), and nuclear-stained
by FxCycle violet (1:10,000; cat: F10347; Invitrogen, Carlsbad,
CA) for 15 minutes. AGS gastric cancer cells were used as a
positive control for each antibody for compensation. Stained
samples were scanned by ImageStream X (Amnis/EMD Milli-
pore, Merck KGaA, Darmstadt, Germany), and data were
analyzed by IDEAS software to provide the median absolute
ﬂuorescence intensity for each sample for each antibody
conjugate. Relative expression levels were determined as the
fold-change compared with the AGS cell line control after
normalizing to the mean aspect ratio of the bright ﬁeld.
CTC Genomic Analyses
After a whole-genome ampliﬁcation step using the
GenomePlex Single Cell Amp Kit (cat: WGA4; Sigma-Aldrich,
St. Louis, MO), targeted Sanger sequencing was performed for
KRAS codons 12/13 and, in 1 selected patient, the CTNNB1 re-
gion (p.G34E mutation), with correlation to parallel results
obtained from next-generation sequencing of a metastaticlymph node biopsy sample using the Foundation One clinical
assay (Foundation Medicine Inc, Cambridge, MA). Concurrent
paired portal venous white blood cell–sorted DNA was used as
sequencing controls for KRAS sequencing.
Immunohistochemistry
After deparafﬁnization and rehydration, tissue sections
were treated with EDTA, pH 9, in a steamer. Anti-Smad4 anti-
body (sc-7966; Santa Cruz Biotechnology, Dallas, TX) (1:20)
was applied on tissue sections for a 1-hour incubation at room
temperature in a humidity chamber. After Tris-buffered saline
wash, the antigen–antibody binding was detected with the
Bond polymer reﬁne detection system (DS9800; Leica Micro-
systems, Buffalo Grove, IL) and 3,30-diaminobenzidine tetra
hydrochloride-positive chromogen (K3468; DAKO, Carpinteria,
CA). Tissue sections were immersed brieﬂy in hematoxylin for
counterstaining and were covered with cover glasses. The
University of Chicago clinical immunohistochemistry (IHC)
laboratory completed staining for p53 (p53 Ab-6, clone DO-1,
1:200; Thermo Scientiﬁc) and p16 (p16 [JC8], sc-56330, 1:50;
Santa Cruz Biotechnology).
Statistical Methods
Results are expressed as means, medians, SDs, and ranges.
Comparisons between numbers of CTCs in peripheral blood
and portal venous blood were performed using paired Student t
test. A P value less than .05 was considered statistically sig-
niﬁcant. Statistical analysis was performed using STATA
12.1 software (StataCorp LP, College Station, TX).
Results
Patient Characteristics, Safety, and Feasibility
The mean age of the 18 patients was 66.1 years (SD,
±10.7 y; range, 51–92 y). There were 14 men (78%) and
4 women (22%), with a racial distribution of 14 Caucasian
patients (78%) and 4 African American patients (22%).
Further patient characteristics, clinical staging, and sample
ﬁndings are summarized (Table 1). EUS-FNA of the primary
tumor conﬁrmed adenocarcinoma in 94.4% of the patients
(17 of 18 patients). Fourteen patients were conﬁrmed to
have pancreatic ductal adenocarcinoma (PDAC), 2 patients
with cholangiocarcinoma, 1 patient with ampullary adeno-
carcinoma, and 1 patient with multiple side-branch intra-
ductal papillary mucinous neoplasms.
In the patients with conﬁrmed PDAC, tumor size ranged
from 27 to 50 mm (mean, 35.8 mm; SD, ±7.9 mm) by EUS or
cross-sectional imaging. Seven of the 14 patients with PDAC
were determined to have borderline resectable disease with
a clinical stage of IIB or lower; however, all 7 patients had
nonceliac axis or superior mesenteric artery vascular
involvement characterized by either abutment or encase-
ment of the portal vein, hepatic artery, or splenic artery.
Patients were observed immediately under EUS guid-
ance after portal venous blood sampling for a minimum of
5 minutes in the endoscopy suite and for 45 minutes after
the procedure in the recovery area. Telephone calls were
made 24 hours and 7 days after the procedure to further
assess recovery. No immediate or delayed complications
Table 1.Patient and Tumor Characteristics With Associated CTC Enumeration
Diagnosis
Clinical
stage
Primary
tumor
location
Size,
mm Path Age, y Race Sex
Family
history
of PBC
Smoking
history
Alcohol
history CA 19-9
Peripheral
CTC test
in 7.5 mL
of blood
Portal vein
CTC test
in 7.5 mL
of blooda
Chemotherapy
before CTC
Distant
metastases Resectable
Pancreas mass IIA Body 27 AC 77 Cauc M No Former None Increasedb 0 101 No No Borderline
Pancreas mass IIA Body 30 AC 92 Cauc F Never Active,
mild
428 0 14 No No Borderline
Pancreas mass
and IPMT
II Head and
tail
36 AC 71 Cauc M No Former None 3411 0 75 No No Borderline
Pancreas mass IIB Head 40 AC 65 Cauc F No Never Active,
mild
569 0 62 No No Borderline
Peripancreatic
mass and
duodenal nodule
IIB Head 50 AC with
NET
features
61 Cauc M No Former Former 55 0 265 Yes No Borderline
Pancreas mass IIB Head 43 AC 51 Cauc M Yes Never None 238 0 1 (1) Yes No Borderline
Pancreas mass IIB Neck 34 AC 70 Cauc F No Active None 1595 1 23 (16) No No Borderline
Pancreas mass III Body 40 AC 66 AAM M No Former Former 93 0 9 No No Unresectable
Pancreas mass III Neck 30 AC 74 Cauc M No Former Former 642 0 102 No No Unresectable
Pancreas mass IV Body 30 AC 64 Cauc M No Never Former 7896 0 132 No Yes (to liver) Unresectable
Pancreas mass IV Head and
neck
50 AC 58 AAM M No Never None 15,300 0 17 No Yes (to liver) Unresectable
Pancreas mass IV Body 26 AC 57 Cauc F Yes Never None 866,900 2 429 (417) No Yes (to liver) Unresectable
Pancreas mass IV Body 35 AC 56 AAM M No Former Active,
mild
748 7 516 (379) No Yes (to liver) Unresectable
Pancreas mass IV Head 30 AC 64 AAM M Former Former 39.3 0 13 Yes Yes (to liver) Unresectable
Ampullary/distal
CBD stenosis
IIA Ampulla 20 AC 52 Cauc M No Never Active,
mild
877 3 185 No No Resected
Distal CBD mass III Distal CBD 17 Chol 64 Cauc M No Active Former 109 0 23 No No Resected
Hilar bile duct mass IV Hilar 23 Chol 75 Cauc M No Never None 1843 0 45 No Yes (to liver) Unresectable
Pancreas sb-IPMNs N/A Head and
body
80 IPMN 82 Cauc M No Former Former 0 1 No No
AAM, African American; AC, adenocarcinoma; NET, neuroendocrine tumor features; Cauc, Caucasian; Chol, cholangiocarcinoma; CBD, common bile duct; IPMN,
intraductal papillary mucinous neoplasm; IPMT, intrapancreatic mucosal tumor; sb-IPMN, side-branch intraductal papillary mucinous neoplasm; active, mild, deﬁned as no
more than 1 drink/day for women and no more than 2 drinks per day for men.
aCTC values with additional value in parenthesis indicating the replicate.
bNumber not available.
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formation or gastrointestinal bleeding, were observed.CellSearch CTC Enumeration
In all 18 patients, the mean portal venous CTCs/7.5 mL
was 111.8 (SEM, ±35.3; median, 53.5) compared with
0.7 peripheral CTCs/7.5 mL (SEM, ±0.4; median, 0; P < .01)
(Figure 2). In the 17 patients with conﬁrmed PBCs, the
mean portal venous CTCs/7.5 mL was 118.4 (SEM, ±36.8;
median, 62.0; range, 1–516) compared with 0.8 peripheral
CTCs/7.5 mL (SEM, ±0.4; P < .01). Patients with non-
metastatic, resectable, or borderline resectable PBCs had a
mean portal venous CTC/7.5 mL count of 83.2 (median,
62.0; range, 1–265) as compared with patients with unre-
sectable PBCs with a mean portal venous CTC/7.5 mL count
of 157.9 (median, 73.5; range, 9–156; P ¼ .23). To assess the
precision of CTC enumeration by CellSearch, in 4 of 14 pa-
tients a second sample of portal venous blood was aspirated
and, in each patient, the enumeration was replicated with
good correlation between samples (Table 1, values inFigure 2. CTC enumeration from peripheral blood and portal ven
of peripheral and portal venous blood by malignancy type. (B)
and a CTC cluster captured by CellSearch enumeration (DAPI,
± SEM for CTCs enumerated from the peripheral blood and p
dicates a statistically signiﬁcant difference using paired t tes
enumeration per 7.5 mL of portal venous blood (PVB) in all pa
borderline-resectable or resected PBCs vs unresectable PBCs.parentheses). A CellSearch review of samples identiﬁed rare
CTC clusters within portal venous blood (Figure 2B).Pancreatic Ductal Adenocarcinoma
Fourteen patients were diagnosed by EUS-FNA with PC.
In this cohort, all patients had CTCs detected in the portal
vein, as opposed to only 3 patients with peripheral CTCs
detected. The mean portal venous CTCs/7.5 mL was
signiﬁcantly higher at 125.64 (median, 68.5; range, 1–516),
whereas the mean peripheral CTCs/7.5 mL was 0.7 (median,
0; range, 0–7; P ¼ .01). In 3 patients who had received
chemotherapy before portal vein sampling, all continued to
have portal vein CTCs detected, ranging from 1 to 265
CTCs/7.5 mL.
Biliary Tract Cancers
Two patients, 1 patient with stage III (resectable) and
the other patient with stage IV (unresectable) chol-
angiocarcinoma, had a CTC enumeration of 23 CTCs/7.5 mLous blood. (A) Summary table of CTC enumeration per 7.5 mL
Representative immunoﬂuorescence staining of a single CTC
magenta; CK, green) (C) Vertical scatter plot with the means
ortal venous blood in patients with conﬁrmed PBCs. Bar in-
t. (D) Box and whisker plot with individual points for CTC
tients with conﬁrmed PBCs and the subset of patients with
IPMN, intraductal papillary mucinous neoplasm.
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although both patients had a complete absence of peripheral
CTCs. A patient with stage IIA ampullary adenocarcinoma
(invasion of duodenal wall and pancreas) had 185 CTCs/7.5
mL of portal venous blood compared with a peripheral CTC
count of 3 CTCs/7.5 mL.
Nonmalignant Intraductal Papillary Mucinous
Neoplasm
A single patient with multiseptated cystic lesions
consistent with side-branch intraductal papillary mucinous
neoplasms was assessed as a nonmalignant cystic lesion
control and was found to have 1 detected CTC in portal
venous blood.
Exploratory Translational Correlative Studies
Expression loss of 1 or more tumor suppressors in PBCs,
including TP53, SMAD4, and p16/CDKN2A, has been corre-
lated with a worse prognosis.17 To evaluate the ability to
determine relative expression levels of these proteins in the
isolated EpCAMþ, DAPIþ CTCs from CD45-depleted portal
venous blood (Figure 3A), we included immunoﬂuorescent
staining of these 3 proteins during the EpCAM ﬂow
cytometry via ImageStream technology and compared the
relative signal intensity with AGS control cell lines
(Figure 3B) with known high/low expression of each
respective protein. EpCAMþ ﬂow identiﬁed individual CTCs
(Figure 3C) and CTC clusters (Figure 3D). The CTCs showed
a relative gain of p53 (1.3-fold higher than controls), and
smad4 protein expression (1.6-fold higher than controls),
with reduced p16 expression (0.45-fold) relative to the AGS
control cells (Figure 3E). Immunohistochemistry of a met-
astatic lymph node from this patient conﬁrmed the loss of
p16 expression, positive expression of smad4, and hetero-
geneous levels of p53 expression (Figure 3F). The CTC
immunoﬂuorescence patterns of these proteins also were
compared with IHC of AGS cells with relatively similar
patterns of expression. Further representative portal
venous CTCs in an additional 4 patients are shown in
Supplementary Figure 1.
Genomic sequencing of DNA extracted from the same
metastatic lymph node biopsy as described earlier (Fo-
undation One) showed the MAP2K1:NM_002755:c.
167A>C_p.Q56P (0.13,1125, PIK3CA:NM 006218:c.331A>G
p.K111E [0.13,765]), and CTNNB1:NM_001904:c.101G>A_p.
G34E (0.06,851) mutational proﬁle. TP53, SMAD4, p16/
CDKN2A, and commonly mutated KRAS all were wild type. To
conﬁrm that the EpCAMþ portal venous CTCs indeed were
derived from the pancreatic tumor, we performed targeted
sequencing of the CTNNB1 region (p.G34E mutation) within
thewhole-genome–ampliﬁedportal venousCTC-derivedDNA.
The mutation also was identiﬁed in this portal venous blood–
derived sample (Figure 4). KRAS codons 12/13 sequencing,
which also was tested given its high frequency of mutation in
PBCs, was conﬁrmed as wild type and was consistent with the
primary tumor proﬁle. In 3 additional patients, KRAS codons
12/13 sequencing of whole-genome–ampliﬁed portal venous
CTC-derived DNA identiﬁed the presence of Gly13Asp(GGC>GAC) mutations supportive of derivation from primary
malignancy (Supplementary Figure 2).Discussion
The results from this study show that minimally invasive
EUS-guided acquisition of portal venous blood for CTC
enumeration and isolation is feasible and safe in PBCs and,
more importantly, is capable of identifying CTCs in portal
venous blood (mean, 83.2 CTCs/7.5 mL; median, 62 CTCs/
7.5 mL), with relative paucity in peripheral blood (mean,
0.4 CTCs/7.5 mL; median, 0 CTCs/7.5 mL) in nonmetastatic
borderline resectable PBCs. We also conﬁrmed that isolation
of CTCs from portal venous blood provides a sufﬁcient
quantity of cells to perform genomic and proteomic tumor
proﬁling successfully.
CTCs enumerated from the peripheral blood have been
shown to be informative biomarkers for progression-free
survival and overall survival in patients with metastatic
breast,10 prostate,18 and colon cancers.19 Relative to these
other epithelial malignancies, the CellSearch EpCAM-pos-
itive–dependent system consistently has identiﬁed low
numbers of peripheral blood CTCs in PC.20 Regardless of
methodology, whether by antibody-mediated immuno-
capture of epithelial surface markers (EpCAM/MUC1),
microﬂuidic selection,11 or size-based ﬁltration,20 the ability
to detect peripheral blood CTCs have been limited to met-
astatic PC. Initial research into the ability to detect PC CTCs
has focused predominantly on metastatic disease. A pre-
liminary study of 16 patients with metastatic PC identiﬁed a
mean of 2 CTCs/7.5 mL of peripheral blood.15 Kurihara
et al21 subsequently evaluated 26 patients with PC, of whom
25 had stage IV disease and 1 had stage III disease. In this
cohort, the stage III patient had no detected peripheral
blood CTCs and only 11 of 25 of the stage IV patients had
measurable CTCs. In the 11 patients with peripheral blood
CTCs, the median was 5 CTCs/7.5 mL (range, 1–105 CTCs/
7.5 mL; mean, 17 CTCs/7.5 mL). Negin et al22 studied
40 patients with metastatic PC and found 50% of patients to
have detectable peripheral blood CTCs, with a median of
fewer than 0.5 CTCs/7.5 mL (range, 0–20 CTCs/7.5 mL).
Recently, the CellSearch EpCAMþ system was compared
with a size-based, surface marker–independent ﬁltration
method (isolation by the size of the epithelial tumor cells
[ISET]) in 31 patients with metastatic or inoperable PC.20
Similarly, the CellSearch system identiﬁed a median num-
ber of 0 CTCs/7.5 mL (range, 0–144 CTCs/7.5 mL) and the
size-based ﬁltration method identiﬁed a slightly higher
number with median of 9 CTCs/7.5 mL (range, 0–240 CTCs/
7.5 mL).
The lack of efﬁcient CTC isolation in peripheral blood has
resulted in increased interest in alternative platforms
including microﬂuidic capture. A recent report identiﬁed
circulating epithelial cells using an immunocapture, micro-
ﬂuidic capture method in pancreatic cystic lesions and in
11 patients with PC.23 In the PC cohort, 7 patients had stage
IV disease, with the remaining 4 patients diagnosed with
stages I–III disease. In 3 of 4 patients with nonmetastatic
disease, circulating, nonleukocyte, nucleated cells were
Figure 3. Tumor-suppressor genes, p16/CDKN2A, TP53, and SMAD4 protein expression in AGS control cells and portal
venous CTCs. (A) Flow cytometry of CD45-depleted portal venous blood gated by ImageStream for EpCAMþ, DAPIþ CTCs.
Representative immunoﬂuorescent staining of the proteins in (B) individual AGS control cells and (C) portal venous CTCs
during EpCAMþ ﬂow cytometry via ImageStream technology. (D) Representative immunoﬂuorescent staining of the proteins in
CTC clusters identiﬁed in portal venous blood. (E) Median intensity for immunoﬂuorescence of CTC p53, smad4, p16 proteins
relative to AGS control cell line normalized to mean cell size (mean aspect ratio of the bright ﬁeld). (F) Immunohistochemistry
conﬁrmation of positive smad4, loss of p16, and heterogeneous p53 expression in a metastatic lymph node relative to AGS
control cells and positive control tissues (40 magniﬁcation; scale bars: 50 mm).
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Figure 4. Conﬁrmation of
CTNNB1 mutation detec-
ted in CTC DNA. Top 2
sequences show reference
protein (top row) and
complementary DNA
(cDNA) (second row) se-
quences as G (glycine) and
GGA, respectively. Bottom
2 sequencing traces show
forward GAA (third row)
and reverse TTC (bottom
row) sequencing of portal
venous CTCs isolated
from the patient consistent
with G34E missense
mutation as found in a
metastatic lymph node.
Red boxes highlight the
sequencing location of the
CTNNB1 gene with G>A
nucleotide change result-
ing in a G34E mutation.
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discrepancy in enumeration relative to our investigation
likely is owing in part to the sensitive, but nonspeciﬁc,
methodology in deﬁning a circulating epithelial or tumor
cell. Rhim et al23 used a deﬁnition of CD45-, DAPIþ, how-
ever, when a more stringent deﬁnition was used, namely
CKþ, CD45-, DAPIþ, the numbers of cells in the 2 reported
stage IV pancreatic cancer patients were reduced, with
levels decreasing to less than those for pancreatic cyst le-
sions. Yu et al24 similarly used a microﬂuidic platform with
high EpCAMþ CTC capture in the peripheral blood, how-
ever, the use of a single ﬂuorescence channel for EpCAM and
cytokeratin (CK) resulted in an inability to distinguish if the
positive signal was coming from EpCAM, CK, or both.
Although microﬂuidic platforms hold a lot of promise, the
varied methodologies and enumeration criteria along with
rapid advances in technology25,26 still require validation
with regard to balancing CTC isolation sensitivity with
purity.27
The paucity of CTCs identiﬁed in the peripheral blood of
patientswith PC has been attributed to hepatic sequestration.
Hematogenous dissemination via the portal venous circula-
tion is supported further by the predominant location of
gastrointestinal metastases, including PC, to the liver. CTCs in
portal venous blood have been described via intraoperative
acquisition in patients with colorectal liver metastases, in
which portal venous blood CTC numbers were signiﬁcantly
higher compared with peripheral blood (median, 87 vs
1 CTC/7.5 mL, respectively).13 Our ﬁndings of signiﬁcantly
higher levels of EUS-acquired/CellSearch-identiﬁed CTCs in
nonmetastatic portal venous blood compared even with
metastatic peripheral blood is consistent with the following
hypotheses: (1) tumor cells are shed into the vasculaturebefore the clinical/radiologic detection of metastases, and (2)
CTCs from the primary tumor are being ﬁltered during their
transit through the hepatic portal circulation, resulting in
fewer cells entering the systemic circulation. These points
emphasize the importance of the blood collection site for CTC
detection in PC curative-intent scenarios, and likely any tu-
mor draining primarily via the portal venous system. Given
the safety proﬁle of EUS and no demonstrated complications
with EUS-guided portal vein sampling, portal venous blood
CTC enumeration may rapidly become adjunctive to current
methods of PC risk stratiﬁcation.
CTC enumeration, via EUS-guided portal venous blood
sampling, has the potential to provide clinical utility with
prognostic stratiﬁcation and therapeutic decision making. In
this study, we show the ability to use CTCs fromportal venous
blood, at the time of diagnosis, to determine the expression of
tumor-suppressor genes, p16/CDKN2A, TP53, and SMAD4,
which are inactivated most frequently in PCs, but any other
protein of interest also could be assessed. Smad4, an intra-
cellular component of the transforming growth factor-b
signaling pathway, is inactivated in approximately 60%ofPCs
and is associated with a poor prognosis.28,29 The shorter
overall survival and increased risk of distant metastases has
led researchers to suggest sparing patients the risk of
pancreatic surgery, particularly in borderline resectable pa-
tients with concomitant SMAD4 gene inactivation.30 In 1 pa-
tient with stage IV metastatic PC, we identiﬁed increased
smad4 protein expression in portal venous CTCs (1.6-fold
increased relative to controls) (Figure 3E), which was
conﬁrmed by DNA sequencing and protein expression with
IHC from a metastatic lymph node. The p16/CDKN2A gene
encoding the protein p16 is inactivated in the majority of PCs
via promoter methylation, missense mutations, or deletions
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tient, despite having a nonmutated p16/CDKN2A, we identi-
ﬁed loss of p16 protein expression by IHC in the lymph node
as well as similar expressions in portal venous CTCs and
control cells. Although pathologic diagnoses of PCs frequently
aremade via EUS-guided FNA cytology examination, we show
here that EUS-guided portal venous blood sampling, at the
time of diagnosis and/or after neoadjuvant therapy, can
enumerate CTCs and allow for molecular characterization
of speciﬁc cancer-associated genes/proteins with the poten-
tial to provide guidance for preoperative risk stratiﬁcation
and/or selecting neo-adjuvant chemotherapy. The ability
to isolate portal venous blood CTCs and complete tumor
molecular proﬁling serially over timemay provide signiﬁcant
information that will facilitate personalized clinical decision
making.
In addition to the direct clinical beneﬁts, EUS-guided
portal venous blood sampling of extravasated primary tu-
mor cells in the form of CTCs may provide select tissue
specimens to further investigate metastatic tumor biology
during a critical window period of hematogenous spread
because emerging evidence suggests that occult metastatic
seeding may occur before large primary tumor formation
and even detectable invasive carcinoma.33,34 CTCs now are
recognized to represent a heterogeneous population of
cells,11,12 including apoptotic cells, cells undergoing
epithelial-to-mesenchymal transition with loss of epithelial
markers, epithelial cells, and cell clusters. There has been
increasing evidence that cell clusters may be the precursor
population responsible for distant organ metastatic seed-
ing35 and here we show that portal vein blood sampling can
identify CTC clusters. CTCs already have been analyzed with
next-generation sequencing,36 and analyzing portal vein
CTCs likely will shed new light on the biology of PBC
metastases.11
We have shown that portal venous CTCs are far more
common and higher in absolute numbers than peripheral
blood CTCs. We also have shown the feasibility of obtaining
portal venous CTCs noninvasively via EUS, as well as the
capability to characterize these isolated cells molecularly.
Future prospective studies will deﬁne the role of portal vein
CTCs as prognostic and/or predictive biomarkers in the
perioperative setting.
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Supplementary Figure 1. Tumor-suppressor genes, p16/CDKN2A, TP53, and SMAD4 protein expression in AGS control cells
and portal venous CTCs. (A) Representative immunoﬂuorescent staining of the proteins in individual AGS control cells. (B–E)
Representative ImageStream immunoﬂuorescence images of p53, smad4, and p16 proteins in CD45-depleted EpCAMþ,
DAPIþ portal venous CTCs and associated median intensity for immunoﬂuorescence relative to AGS controls normalized to
mean cell size (mean aspect ratio of the bright ﬁeld) in individual patients with (B) stage IIB pancreatic cancer, (C) stage III
pancreatic cancer, (D) stage IV pancreatic cancer, and (E) stage IV pancreatic cancer.
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Supplementary Figure 2. Conﬁrmation of KRAS mutations detected in portal venous CTC DNA. Whole-genome ampliﬁcation
followed by targeted Sanger sequencing chromatograms of KRAS codons 12/13 detecting the presence of Gly13Asp
(GGC>GAC) mutations in individual patients with (A) stage IIB pancreatic cancer, (B) stage IV pancreatic cancer, and (C) stage
IV pancreatic cancer. Concurrent, paired portal vein–acquired white blood cell (WBC) fractions were used as sequencing
controls for each patient with no evidence of KRAS codon 12/13 mutations. Yellow highlight indicate codons 12 and 13 of
KRAS. Red arrows indicate the sequencing location of the KRAS gene with Gly13Asp (GGC>GAC) mutation in portal vein
CTCs.
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